{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gouraud H"],"funding":["Agence Nationale de la Recherche","AHRQ HHS","FDA HHS","NHLBI NIH HHS","NIAAA NIH HHS"],"pagination":["e000154"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9978683"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1(1)"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the impact of conducting all possible pooled analyses across different combinations of randomised controlled trials and endpoints.<h4>Design</h4>Multiverse analysis, consisting of numerous pooled analyses of individual participant data.<h4>Setting</h4>Individual patient data from 12 randomised controlled trials comparing canagliflozin treatment with placebo, shared on the Yale University Open Data Access project (https://yoda.yale.edu/) platform, up to 16 April 2021.<h4>Participants</h4>15 094 people with type 2 diabetes mellitus.<h4>Main outcome measures</h4>Pooled analyses estimated changes in serum glycated haemoglobin (HbA1c), major adverse cardiovascular events, and serious adverse events at weeks 12, 18, 26, and 52. The distribution of effect estimates w"],"journal":["BMJ medicine"],"pubmed_title":["Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis."],"pmcid":["PMC9978683"],"funding_grant_id":["R01 HL144644","R01 HS025164","ANR-17-CE-36-0010-01","R01 HS022882","U01 FD005938","K01 AA028258"],"pubmed_authors":["Wallach JD","Boussageon R","Naudet F","Ross JS","Gouraud H"],"additional_accession":[]},"is_claimable":false,"name":"Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis.","description":"<h4>Objective</h4>To evaluate the impact of conducting all possible pooled analyses across different combinations of randomised controlled trials and endpoints.<h4>Design</h4>Multiverse analysis, consisting of numerous pooled analyses of individual participant data.<h4>Setting</h4>Individual patient data from 12 randomised controlled trials comparing canagliflozin treatment with placebo, shared on the Yale University Open Data Access project (https://yoda.yale.edu/) platform, up to 16 April 2021.<h4>Participants</h4>15 094 people with type 2 diabetes mellitus.<h4>Main outcome measures</h4>Pooled analyses estimated changes in serum glycated haemoglobin (HbA1c), major adverse cardiovascular events, and serious adverse events at weeks 12, 18, 26, and 52. The distribution of effect estimates w","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-06-13T06:13:08.572Z","creation":"2024-11-12T18:08:51.659Z"},"accession":"S-EPMC9978683","cross_references":{"pubmed":["36936564"],"doi":["10.1136/bmjmed-2022-000154"]}}